Everolimus Resistance in Clear Cell Renal Cell Carcinoma: miRNA-101 and HIF-2α As Molecular Triggers?
- 3 July 2019
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 15 (20) , 2361-2370
Abstract
Aim: The majority of clear cell renal cell carcinoma patients develop resistance to mTOR inhibitors. Materials & methods: As an in vitro model four cell lines were used: HKC-8, 786- O, RCC-FG-2 and...Keywords
Funding Information
- Norte Portugal Regional Operational Programme (SFRH/ BPD/111114/2015)
- Research Center of the Portuguese Oncology Institute of Porto
This publication has 30 references indexed in Scilit:
- Molecular pathways in renal cell carcinomaCurrent Opinion in Oncology, 2015
- Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular CarcinomaDigestive Diseases and Sciences, 2014
- MicroRNAs in cancer: biomarkers, functions and therapyTrends in Molecular Medicine, 2014
- MicroRNA expression signatures of stage, grade, and progression in clear cell RCCCancer Biology & Therapy, 2013
- Targeting DNA-PKcs and ATM with miR-101 Sensitizes Tumors to RadiationPLOS ONE, 2010
- The genetic basis of kidney cancer: a metabolic diseaseNature Reviews Urology, 2010
- Resistance to targeted therapy in renal-cell carcinomaThe Lancet Oncology, 2009
- mTORC2 Activity Is Elevated in Gliomas and Promotes Growth and Cell Motility via Overexpression of RictorCancer Research, 2007
- Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted TherapiesThe Oncologist, 2007
- Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the CytoskeletonCurrent Biology, 2004